Course Overview

Breast Cancer: Shifting from Early Detection to Prevention

This presentation will review estrogen metabolism and discuss which SNPs are associated with breast cancer.
Write your awesome label here.

2021 Annual Conference

October 29-31, 2021

Required Lessons

1 lesson with video, quiz, and evaluation

Time to Complete

45 minutes

CME Eligible*

.75 credits
Click the buttons below to view detailed information on this course  
Course Info
Course Faculty
Accreditation/CME

What you will learn

 Course Summary

There seems to be an increase incidence of premenopausal breast cancer in the United States. Traditionally, HRT has been blamed as a causative factor and also genetics with BRAC 1 and 2. However, these premenopausal patients are not on hormone therapy and many are negative for BRAC genes. My hypothesis is that there are other single nucleotide pleomorphisms (SNPs) that put a patient at an increased risk of breast cancer, namely MTHFR 677, MTHFR 1298, and COMT. MTHFR and COMT genes are involved in methylation processes in the body. This process is a large component of Phase 2 detoxification, especially for estrogen. My theory is that patients with SNPs in MTHFR and COMT have an impaired ability to get rid of estrogens and thus have an accumulation or back up of Estrone or the toxic metabolite 4-OH Estrone which can increase the risk of breast cancer. As a result, there is an imbalance in the hormones that cause hyperplasia (estrogens) and regulation and apoptosis (progesterone) in the breast. In addition, my belief is that this balance in proliferation and apoptosis has an influence on cancer risk. This presentation will review estrogen metabolism and discuss which SNPs are associated with breast cancer. Epigenetic modulation of the enzymes involved in estrogen detoxification will also be discussed. A detailed evaluation of hormones, estrogen metabolism and identification of those SNPs that increase the risk of breast cancer will allow us to shift to more prevention instead of just early detection. Other gynecological conditions such as endometriosis and fibroids are influenced by this imbalance in estrogen and progesterone. An in depth focus on hormones in high risk patients will lead to more prevention of breast cancer.

 Course Objectives

By the end of this course, learners will be able to:
  • Review Estrogen detoxification and discuss epigenetic modulation of the enzymes involved
  • Demonstrate which SNPs may possibly be involved with breast cancer risk
  • Many studies have already been published regarding the SNPs and review articles have been published regarding estrogen metabolites and breast cancer risk.
See course outline below for additional information.

This course includes:

  • Video recording
  • Downloadable audio
  • Speaker handout(s)
  • 1 Quiz
  • 1 Evaluation
  • Certificate of Completion

Course Faculty

Tara Scott, MD, FACOG, ABOIHM, ABAARM, CNMP

Bio

Fellow of American College of OB/GYN; Advanced Fellow and certified in Anti-aging, Regenerative, and Functional Medicine; Board Certified, American Board of Integrative Medicine, Certified Menopause Practitioner through the North American Menopause Society; Clinical Associate Professor of OB/GYN at Northeast Ohio Medical University; Chief Medical Officer, Revitalize Medical Group, Medical Director of Integrative Medicine at Summa Health Systems.  

Dr. Tara Scott graduated from Northeast Ohio University College of Medicine and completed her residency with Summa Health Systems at Akron City Hospital in Ohio. She recently "retired" from OB/GYN after almost 20 years to focus on functional and integrative medicine. She is an Associate Clinical Professor at Northeast Ohio Medical University, where she teaches OB/GYN residents.  

Dr. Scott is a certified menopause practitioner with the North American Menopause Society and a fellow of the American College of Obstetrics and Gynecology. She first became involved with hormone and integrative medicine while practicing as an OB/GYN. Her empathy for patients experiencing hormone-related issues led her to become trained as an advanced fellow and certified by the American Academy of Anti-Aging Medicine. The evidence-based practices she employed helped many patients conquer chronic wellness issues. She then started Revitalize Medical Group, where she serves as the Chief Medical Officer. In 2016 she obtained an additional board certification in Integrative Medicine. Dr. Scott is passionate about educating the medical community on the advances in evidence-based hormone therapy. She lectures around the community to raise awareness about wellness and hormone balance and has taught doctors in 5 continents. She is Medical Director for Summa Health in Akron, OH where she will develop and run and Integrative Medicine program.

Disclosure

No financial relationships with any ineligible companies to disclose.

Accreditation and CME

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, Irvine School of Medicine and the Academy of Integrative Health & Medicine. The University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. 

This activity is in compliance with California Assembly Bill 1195, which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. For specific information regarding Bill 1195 and cultural and linguistic competency, please visit the
CME website.

*CME/CEU Credits

The University of California, Irvine School of Medicine designates this enduring materials for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other healthcare professionals
 completing this activity will be issued a certificate of participation. To successfully earn credit, participants must review the content, complete a quiz with a score of 75% or higher, and submit an evaluation. This course is CME-eligible ending on December 31, 2022. After this date, you will continue to have access to your purchased content, however you will no longer be able to claim CME credits for your participation in the course.
The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California, Irvine School of Medicine and/or the Academy of Integrative Health & Medicine.

Enroll Now!

This course is self-paced with no set beginning or end date. You may complete this course on your own schedule and pace. Enrolling in and purchasing this course grants you access to its contents in perpetuity. All required course activities must be completed to earn any eligible continuing education credit(s) and obtain a certificate of completion for this course.